Menu Back toSession 2: Is Zynteglo representative for the ATMPs failure in Europe? Are EU systems broken for innovative therapies?

Innovative Therapies in Europe

DIA-EUCOPE Workshop: 5 Years of ATMPs on the Market - Lessons Learned

Session 2: Is Zynteglo representative for the ATMPs failure in Europe? Are EU systems broken for innovative therapies?

Session Chair(s)

Alexander Natz, JD

Alexander Natz, JD

  • Secretary General
  • European Confederation of Pharmaceutical Entrepreneurs, Belgium

Topics covered in this session include:

  • Case study & domino effect
  • The regulatory aspects
  • Historical background for withdrawals

Speaker(s)

Sophie Schmitz

Sophie Schmitz

  • Managing Partner
  • P4A Partners for Access, Netherlands
Oswald Bentinck

The Zolgensma Experience – Can one-time ATMP’s be successfully commercialized in Europe?

Oswald Bentinck

  • Vice President, Global Head of Value & Access
  • Rocket Pharmaceuticals, Inc., United States

Contact us

Registration Questions?

Send Email
+41 61 225 51 51